KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Cash & Equivalents (2020 - 2025)

Recursion Pharmaceuticals (RXRX) has disclosed Cash & Equivalents for 6 consecutive years, with $743.3 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash & Equivalents rose 25.06% year-over-year to $743.3 million, compared with a TTM value of $743.3 million through Dec 2025, up 25.06%, and an annual FY2025 reading of $743.3 million, up 25.06% over the prior year.
  • Cash & Equivalents was $743.3 million for Q4 2025 at Recursion Pharmaceuticals, up from $659.8 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $743.3 million in Q4 2025 and bottomed at $214.1 million in Q1 2021.
  • Average Cash & Equivalents over 5 years is $468.6 million, with a median of $463.9 million recorded in 2022.
  • The sharpest move saw Cash & Equivalents surged 137.23% in 2022, then tumbled 37.37% in 2024.
  • Year by year, Cash & Equivalents stood at $285.1 million in 2021, then skyrocketed by 92.87% to $549.9 million in 2022, then fell by 28.79% to $391.6 million in 2023, then surged by 51.79% to $594.4 million in 2024, then increased by 25.06% to $743.3 million in 2025.
  • Business Quant data shows Cash & Equivalents for RXRX at $743.3 million in Q4 2025, $659.8 million in Q3 2025, and $525.1 million in Q2 2025.